| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.904 | 0.001 | 0.94 | Poly(ADP-ribose) polymerase inhibitor | 0.94 0.001 DBMET03439 0.682 0.002 DBMET03440 0.728 0.002 DBMET03441 | DBMET03439 | |
| 0.88 | 0.001 | 0.922 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.922 0.001 DBMET03439 0.646 0.002 DBMET03440 0.694 0.002 DBMET03441 | DBMET03439 | |
| 0.68 | 0.002 | 0.718 | Poly(ADP-ribose) polymerase 2 inhibitor | 0.718 0.002 DBMET03439 0.394 0.003 DBMET03440 0.562 0.003 DBMET03441 | DBMET03439 | |
| 0.23 | 0.025 | 0.23 | Hemostatic | 0.189 0.037 DBMET03439 | ||
| 0.323 | 0.143 | 0.337 | Cyclophilin D inhibitor | 0.268 0.193 DBMET03439 0.337 0.132 DBMET03440 0.315 0.149 DBMET03441 | DBMET03440 | |
| 0.176 | 0.011 | 0.183 | Phosphodiesterase 3A inhibitor | 0.183 0.01 DBMET03439 0.091 0.041 DBMET03440 0.154 0.015 DBMET03441 | DBMET03439 | |
| 0.165 | 0.004 | 0.165 | Fatty acid synthase inhibitor | 0.06 0.035 DBMET03439 0.094 0.013 DBMET03440 0.163 0.004 DBMET03441 | ||
| 0.285 | 0.127 | 0.432 | Antiobesity | 0.236 0.17 DBMET03439 0.432 0.055 DBMET03440 | DBMET03440 | |
| 0.168 | 0.027 | 0.168 | Antihistaminic | 0.112 0.047 DBMET03439 0.081 0.076 DBMET03441 | ||
| 0.157 | 0.027 | 0.157 | Histamine antagonist | 0.101 0.047 DBMET03439 | ||
| 0.18 | 0.051 | 0.264 | Cyclin-dependent kinase 8 inhibitor | 0.264 0.013 DBMET03439 | DBMET03439 | |
| 0.253 | 0.125 | 0.362 | Vasodilator, peripheral | 0.362 0.069 DBMET03439 | DBMET03439 | |
| 0.148 | 0.025 | 0.148 | Histamine H1 receptor antagonist | 0.13 0.029 DBMET03439 | ||
| 0.105 | 0.005 | 0.105 | Neurokinin 3 antagonist | 0.071 0.013 DBMET03439 0.059 0.021 DBMET03440 0.069 0.013 DBMET03441 | ||
| 0.153 | 0.055 | 0.171 | MAP3K9 inhibitor | 0.171 0.034 DBMET03439 0.159 0.048 DBMET03440 0.135 0.085 DBMET03441 | DBMET03439 | |
| 0.101 | 0.012 | 0.101 | Histamine H3 receptor antagonist | 0.049 0.027 DBMET03439 0.042 0.032 DBMET03441 | ||
| 0.106 | 0.02 | 0.133 | Phosphodiesterase III inhibitor | 0.133 0.013 DBMET03439 0.109 0.019 DBMET03441 | DBMET03439 | |
| 0.087 | 0.01 | 0.087 | Smo receptor antagonist | 0.071 0.015 DBMET03439 | ||
| 0.198 | 0.123 | 0.198 | Neuropeptide Y2 antagonist | 0.191 0.137 DBMET03441 | ||
| 0.08 | 0.009 | 0.084 | Antiviral (Hepatitis D) | 0.084 0.007 DBMET03439 0.067 0.016 DBMET03440 0.072 0.012 DBMET03441 | DBMET03439 | |
| 0.08 | 0.013 | 0.08 | CC chemokine 5 receptor antagonist | 0.056 0.03 DBMET03440 0.045 0.044 DBMET03441 | ||
| 0.082 | 0.016 | 0.082 | Neurokinin antagonist | 0.055 0.028 DBMET03439 0.047 0.039 DBMET03441 | ||
| 0.102 | 0.045 | 0.102 | Androgen antagonist | 0.078 0.068 DBMET03439 | ||
| 0.07 | 0.016 | 0.074 | Glutamate (mGluR group I) agonist | 0.053 0.028 DBMET03440 0.074 0.014 DBMET03441 | DBMET03441 | |
| 0.088 | 0.035 | 0.088 | Viral attachment inhibitor | 0.081 0.047 DBMET03439 0.088 0.035 DBMET03440 | ||
| 0.064 | 0.013 | 0.064 | Guanylate cyclase stimulant | 0.044 0.028 DBMET03439 | ||
| 0.083 | 0.032 | 0.083 | MAP kinase kinase 8 inhibitor | 0.063 0.058 DBMET03440 0.07 0.045 DBMET03441 | ||
| 0.064 | 0.016 | 0.072 | Glutamate (mGluR5) agonist | 0.05 0.025 DBMET03440 0.072 0.013 DBMET03441 | DBMET03441 | |
| 0.059 | 0.015 | 0.059 | Acetyl-CoA carboxylase inhibitor | 0.041 0.029 DBMET03440 0.055 0.017 DBMET03441 | ||
| 0.238 | 0.194 | 0.383 | Analgesic | 0.383 0.092 DBMET03441 | DBMET03441 | |
| 0.061 | 0.019 | 0.061 | Neurokinin 2 antagonist | |||
| 0.078 | 0.037 | 0.078 | Orexin receptor 1 antagonist | 0.072 0.05 DBMET03439 | ||
| 0.062 | 0.022 | 0.063 | Purinergic P2X antagonist | 0.063 0.021 DBMET03439 0.047 0.036 DBMET03441 | DBMET03439 | |
| 0.059 | 0.02 | 0.082 | Phosphodiesterase 3B inhibitor | 0.082 0.015 DBMET03439 0.05 0.025 DBMET03441 | DBMET03439 | |
| 0.068 | 0.03 | 0.275 | Potassium channel (Ca-activated) blocker | 0.275 0.004 DBMET03441 | DBMET03441 | |
| 0.179 | 0.141 | 0.225 | Cardiotonic | 0.225 0.099 DBMET03439 0.218 0.104 DBMET03441 | DBMET03439 | |
| 0.052 | 0.018 | 0.052 | Neurokinin 1 antagonist | 0.044 0.024 DBMET03439 | ||
| 0.082 | 0.051 | 0.082 | Glutamate receptor agonist | |||
| 0.126 | 0.104 | 0.127 | Heat shock protein 90 antagonist | 0.127 0.102 DBMET03439 | DBMET03439 | |
| 0.067 | 0.045 | 0.067 | Orexin receptor antagonist | |||
| 0.027 | 0.008 | 0.027 | Guanylate cyclase 1 stimulant | |||
| 0.04 | 0.021 | 0.043 | Purinergic P2X7 antagonist | 0.043 0.019 DBMET03439 0.031 0.03 DBMET03441 | DBMET03439 | |
| 0.06 | 0.044 | 0.06 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.057 0.05 DBMET03439 | ||
| 0.072 | 0.058 | 0.072 | Potassium channel (Tandem pore domain) blocker | 0.07 0.064 DBMET03441 | ||
| 0.059 | 0.046 | 0.059 | Glutamate (mGluR) agonist | |||
| 0.024 | 0.014 | 0.024 | Acetyl-CoA carboxylase 2 inhibitor | 0.023 0.015 DBMET03441 | ||
| 0.02 | 0.012 | 0.02 | Acetyl-CoA carboxylase 1 inhibitor | 0.018 0.013 DBMET03441 | ||
| 0.017 | 0.01 | 0.019 | Thyroid hormone alpha agonist | 0.019 0.008 DBMET03439 | DBMET03439 | |
| 0.07 | 0.064 | 0.07 | CC chemokine receptor antagonist | |||
| 0.06 | 0.056 | 0.06 | Phosphodiesterase 4B inhibitor | |||
| 0.056 | 0.053 | 0.056 | Purinergic P2 antagonist | |||
| 0.032 | 0.029 | 0.032 | Orexin receptor 2 antagonist | |||
| 0.072 | 0.07 | 0.077 | Phosphodiesterase IV inhibitor | 0.077 0.064 DBMET03439 | DBMET03439 | |
| 0.089 | 0.088 | 0.089 | Hedgehog signaling inhibitor | |||
| 0.039 | 0.038 | 0.04 | Stearoyl-CoA desaturase inhibitor | 0.04 0.036 DBMET03440 0.04 0.038 DBMET03441 | DBMET03441 | |
| 0.077 | 0.088 | 0.144 | Vascular endothelial growth factor 1 antagonist | 0.144 0.043 DBMET03439 | DBMET03439 | |
| 0.041 | 0.055 | 0.049 | Prolyl endopeptidase inhibitor | 0.049 0.038 DBMET03441 | DBMET03441 | |
| 0.042 | 0.057 | 0.055 | Phosphodiesterase 4C inhibitor | 0.055 0.04 DBMET03439 | DBMET03439 | |
| 0.145 | 0.161 | 0.255 | Cyclic AMP phosphodiesterase inhibitor | 0.255 0.061 DBMET03439 | DBMET03439 | |
| 0.081 | 0.098 | 0.103 | Alpha 2d adrenoreceptor antagonist | 0.103 0.043 DBMET03439 | DBMET03439 | |
| 0.003 | 0.022 | 0.01 | Insulin like growth factor 3 antagonist | 0.01 0.003 DBMET03440 0.007 0.004 DBMET03441 | DBMET03440 | |
| 0.05 | 0.076 | 0.056 | Phosphodiesterase 1A inhibitor | 0.056 0.052 DBMET03439 | DBMET03439 | |
| 0.245 | 0.273 | 0.366 | Antiinflammatory | 0.317 0.199 DBMET03440 0.366 0.161 DBMET03441 | DBMET03441 | |
| 0.048 | 0.078 | 0.065 | HIV-1 reverse transcriptase inhibitor | 0.065 0.053 DBMET03439 | DBMET03439 | |
| 0.05 | 0.081 | 0.108 | Check point kinase 1 inhibitor | 0.108 0.025 DBMET03439 | DBMET03439 | |
| 0.091 | 0.123 | 0.112 | Phosphodiesterase inhibitor | 0.112 0.091 DBMET03439 | DBMET03439 | |
| 0.055 | 0.088 | 0.118 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.118 0.028 DBMET03439 | DBMET03439 | |
| 0.033 | 0.068 | 0.052 | Cannabinoid CB2 receptor agonist | 0.052 0.04 DBMET03441 | DBMET03441 | |
| 0.039 | 0.076 | 0.078 | Cannabinoid receptor agonist | 0.078 0.036 DBMET03441 | DBMET03441 | |
| 0.082 | 0.122 | 0.205 | MAP kinase kinase inhibitor | 0.205 0.027 DBMET03440 0.139 0.058 DBMET03441 | DBMET03440 | |
| 0.046 | 0.087 | 0.084 | CDC7 inhibitor | 0.084 0.033 DBMET03439 | DBMET03439 | |
| 0.024 | 0.069 | 0.035 | Somatostatin 4 agonist | 0.035 0.028 DBMET03439 | DBMET03439 | |
| 0.013 | 0.06 | 0.024 | Motilin receptor agonist | 0.024 0.014 DBMET03439 | DBMET03439 | |
| 0.032 | 0.085 | 0.087 | Cannabinoid CB1 receptor agonist | 0.087 0.025 DBMET03441 | DBMET03441 | |
| 0.066 | 0.12 | 0.075 | MAP kinase 7 inhibitor | 0.075 0.065 DBMET03441 | DBMET03441 | |
| 0.036 | 0.098 | 0.072 | Alpha 1b adrenoreceptor antagonist | 0.072 0.052 DBMET03439 | DBMET03439 | |
| 0.044 | 0.115 | 0.067 | Rho-associated kinase II inhibitor | 0.067 0.061 DBMET03439 | DBMET03439 | |
| 0.025 | 0.099 | 0.036 | 5 Hydroxytryptamine 2B agonist | 0.036 0.035 DBMET03439 | DBMET03439 | |
| 0.02 | 0.107 | 0.052 | Alpha 1d adrenoreceptor antagonist | 0.052 0.048 DBMET03439 | DBMET03439 | |
| 0.032 | 0.12 | 0.071 | Alpha 1 adrenoreceptor antagonist | 0.071 0.058 DBMET03439 | DBMET03439 | |
| 0.034 | 0.122 | 0.052 | Alpha 1b adrenoreceptor agonist | 0.052 0.031 DBMET03439 | DBMET03439 | |
| 0.109 | 0.197 | 0.174 | 3C-like protease (Human coronavirus) inhibitor | 0.174 0.07 DBMET03441 | DBMET03441 | |
| 0.131 | 0.224 | 0.198 | MAP-kinase-activated kinase 5 inhibitor | 0.198 0.106 DBMET03439 | DBMET03439 | |
| 0.025 | 0.118 | 0.06 | Alpha 1a adrenoreceptor antagonist | 0.06 0.058 DBMET03439 | DBMET03439 | |
| 0.031 | 0.14 | 0.087 | Cannabinoid receptor antagonist | 0.087 0.035 DBMET03441 | DBMET03441 | |
| 0.142 | 0.257 | 0.258 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.258 0.099 DBMET03439 | DBMET03439 | |
| 0.1 | 0.216 | 0.159 | Death-associated protein kinase 3 inhibitor | 0.159 0.109 DBMET03439 | DBMET03439 | |
| 0.04 | 0.156 | 0.076 | ALK inhibitor | 0.076 0.065 DBMET03439 | DBMET03439 | |
| 0.051 | 0.172 | 0.099 | Aurora-B kinase inhibitor | 0.099 0.084 DBMET03439 | DBMET03439 | |
| 0.161 | 0.283 | 0.254 | Calcium channel activator | 0.254 0.142 DBMET03439 | DBMET03439 | |
| 0.01 | 0.133 | 0.067 | 5 Hydroxytryptamine 2C agonist | 0.067 0.016 DBMET03439 | DBMET03439 | |
| 0.026 | 0.158 | 0.068 | Cannabinoid CB1 receptor antagonist | 0.068 0.037 DBMET03441 | DBMET03441 | |
| 0.094 | 0.229 | 0.141 | Pregnane X receptor agonist | 0.141 0.072 DBMET03441 | DBMET03441 | |
| 0.053 | 0.191 | 0.104 | Cyclin-dependent kinase inhibitor | 0.104 0.086 DBMET03439 | DBMET03439 | |
| 0.04 | 0.201 | 0.104 | Polo-like kinase-4 inhibitor | 0.104 0.073 DBMET03439 | DBMET03439 | |
| 0.046 | 0.21 | 0.104 | 5 Hydroxytryptamine 3A agonist | 0.104 0.071 DBMET03439 | DBMET03439 | |
| 0.097 | 0.262 | 0.323 | MAP kinase kinase 4 inhibitor | 0.142 0.079 DBMET03440 0.323 0.004 DBMET03441 | DBMET03441 | |
| 0.076 | 0.247 | 0.216 | Potassium channel blocker | 0.216 0.083 DBMET03441 | DBMET03441 | |
| 0.051 | 0.264 | 0.111 | Activin receptor-like kinase 2 inhibitor | 0.111 0.108 DBMET03439 | DBMET03439 | |
| 0.049 | 0.269 | 0.096 | Activin receptor-like kinase 4 inhibitor | 0.096 0.093 DBMET03439 | DBMET03439 | |
| 0.098 | 0.338 | 0.188 | Angiogenesis inhibitor | 0.188 0.184 DBMET03441 | DBMET03441 | |
| 0.127 | 0.449 | 0.237 | MAP kinase kinase 3 inhibitor | 0.237 0.046 DBMET03440 | DBMET03440 | |
| 0.042 | 0.365 | 0.146 | MAP kinase kinase 2 inhibitor | 0.146 0.125 DBMET03439 | DBMET03439 | |
| 0.028 | 0.359 | 0.364 | Uric acid excretion stimulant | 0.364 0.004 DBMET03440 0.109 0.045 DBMET03441 | DBMET03440 | |
| 0.043 | 0.41 | 0.226 | Antimitotic | 0.226 0.07 DBMET03441 | DBMET03441 | |
| 0.01 | 0.382 | 0.042 | Dopamine transporter inhibitor | 0.042 0.041 DBMET03440 | DBMET03440 | |
| 0.007 | 0.666 | 0.108 | Tubulin antagonist | 0.108 0.093 DBMET03441 | DBMET03441 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |